Sales of Teva’s multiple sclerosis blockbuster Copaxone are likely to peak this year before gradually giving way as more therapeutic options become available, a Teva exec says. The head of global ...
Additional Preclinical Data to be Presented at the Fifth Joint Triennial Congress of ECTRIMS and ACTRIMS Further Elucidate the Anti-inflammatory Mechanism of COPAXONE® JERUSALEM--(BUSINESS WIRE)-- ...
AHMEDABAD, India--(BUSINESS WIRE)--Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) has received final approval from the United States Food and ...
Epinephrine Injection (Auto-Injector) is a prescription medicine in a disposable, prefilled automatic injection device (auto-injector) used to treat life-threatening, allergic emergencies including ...
Approved in 1996, Copaxone ® is the global market leader in the treatment of relapsing-remitting multiple sclerosis (RRMS) Ongoing, prospective, clinical trial follow-up reinforces the established ...
(RTTNews) - Viatris Inc. (VTRS) announced the launch in Canada of Glatiramer Acetate Injection 20 mg/mL for once-daily injection, the first generic bioequivalent version of Teva's Copaxone 20 mg/mL, ...
NEW YORK, Dec 3 (Reuters) - Teva Pharmaceutical Industries Ltd's Copaxone reduced the risk of patients developing multiple sclerosis after they showed an initial sign of the central nervous system ...
TEL AVIV, Israel--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that new data on AJOVY® (fremanezumab) and the burden of migraine in Europe will be ...
JERUSALEM--(BUSINESS WIRE)-- Researchers utilizing an advanced magnetic resonance imaging (MRI) technology to characterize and chart the evolution of MS lesions found that relapsing-remitting multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback